Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100OZ1E
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥2.9bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥1.4bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income−¥1.6bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥393m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥436m2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥442m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.5bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥361m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥312m2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥352m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥227m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥8m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥213m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥227m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥8m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥213m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥51.9bnat 2022-06-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥24.8bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥27.2bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥22.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.6bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥10m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥450m2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-8.132022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-1.752022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-0.072021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥1.662021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-8.132022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-1.752022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-0.072021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥1.642021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio91.3%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 9
SegmentItemPeriodValue
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥198m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 668
ItemContextValueUnit
Revenue IFRSPrior1QuarterDuration1439144000JPY
Revenue IFRSCurrentQuarterDuration4604870000JPY
Cost of sales IFRSPrior1QuarterDuration415086000JPY
Cost of sales IFRSCurrentQuarterDuration2508227000JPY
Gross profit IFRSPrior1QuarterDuration1024057000JPY
Gross profit IFRSCurrentQuarterDuration2096643000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration201890000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration1729781000JPY
Research and development expenses IFRSPrior1QuarterDuration407218000JPY
Research and development expenses IFRSCurrentQuarterDuration760407000JPY
Other income IFRSPrior1QuarterDuration27054000JPY
Other income IFRSCurrentQuarterDuration518000JPY
Other expenses IFRSPrior1QuarterDuration89000JPY
Other expenses IFRSCurrentQuarterDuration0JPY
Operating profit loss IFRSPrior1QuarterDuration441913000JPY
Operating profit loss IFRSCurrentQuarterDuration-393027000JPY
Finance income IFRSPrior1QuarterDuration1977000JPY
Finance income IFRSCurrentQuarterDuration147944000JPY
Finance costs IFRSPrior1QuarterDuration－JPY
Finance costs IFRSCurrentQuarterDuration66104000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration-92033000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration-50012000JPY
Profit loss before tax IFRSPrior1QuarterDuration351857000JPY
Profit loss before tax IFRSCurrentQuarterDuration-361199000JPY
Income tax expense IFRSPrior1QuarterDuration138390000JPY
Income tax expense IFRSCurrentQuarterDuration-134414000JPY
Profit loss IFRSPrior1QuarterDuration213467000JPY
Profit loss IFRSCurrentQuarterDuration-226784000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration213467000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration-226784000JPY
Profit loss IFRSPrior1QuarterDuration213467000JPY
Profit loss IFRSCurrentQuarterDuration-226784000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration1.66
Basic earnings loss per share IFRSCurrentQuarterDuration-1.75
Diluted earnings loss per share IFRSPrior1QuarterDuration1.64
Diluted earnings loss per share IFRSCurrentQuarterDuration-1.75
Profit loss IFRSPrior1YTDDuration-8335000JPY
Profit loss IFRSCurrentYTDDuration-1056081000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration884151000JPY
Financial assets measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration433171000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration884151000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration433171000JPY
Other comprehensive income IFRSPrior1YTDDuration884151000JPY
Other comprehensive income IFRSCurrentYTDDuration433171000JPY
Comprehensive income IFRSPrior1YTDDuration875816000JPY
Comprehensive income IFRSCurrentYTDDuration-622909000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration875816000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration-622909000JPY
Comprehensive income IFRSPrior1YTDDuration875816000JPY
Comprehensive income IFRSCurrentYTDDuration-622909000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass